U.S. Housing Starts Declined in March as Interest Rates Weigh
By Ed Frankl
U.S. housing starts tumbled more than expected in March, reflecting high interest rates that are weighing on construction. Here are the main takeaways from the Commerce Department's report released Tuesday.
--Housing starts, a measure of U.S. home building, dipped 14.7% to a seasonally adjusted rate of 1.32 million.
--Economists polled by The Wall Street Journal had expected starts to decrease 2.7% to 1.48 million.
--Starts were 4.3% lower than the same month last year.
--February's housing starts were revised upward to 1.55 million from 1.52 million.
--Monthly housing starts data are volatile. March data came with a margin of error of 9.9%.
--Residential permits, which can hint at future home construction, fell 4.3% on month to 1.46 million. Economists had expected permits to tick down to 1.51 million.
--The data come after sentiment held steady among home builders in April, as prospective purchasers were more hesitant due to greater expectations that the Federal Reserve would wait before cutting interest rates, according to the National Association of Home Builders on Monday.
Write to Ed Frankl at edward.frankl@wsj.com
(END) Dow Jones Newswires
April 16, 2024 09:03 ET (13:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year